nPhase raises $30M from Viking Global in its first equity round since 2017
The clinical trial data software company says it went nearly a decade without new equity. It plans to expand its AI tools for drug sponsors and contract research organizations and to grow globally.

- Amount
- $30M
- Type
- Series D
- Company
- nPhase
- Lead investor
- Viking Global Investors
- Sector
- Health AI
- Announced
- Nov. 2, 2026
nPhase went almost a decade without selling new shares. The company, which makes software that drug sponsors use to manage clinical trial data, said Nov. 2 that it closed a $30 million Series D led by Viking Global Investors, its first equity raise since 2017.
The announcement, datelined Atlantic Beach, Fla., named no other investors and did not disclose a valuation. nPhase said Viking oversees over $54 billion in public and private holdings.
Why it matters: nPhase is pitching pharmaceutical sponsors on one system that standardizes trial data as it arrives, so AI agents can take over routine work that today, the company says, passes through many separate systems and hand-offs between people. It says its statistical tools can shrink submission work that usually takes four months or more to a matter of weeks.
What nPhase sells
Its flagship platform, nPhase.ai, combines a Unified Data Management System with a Statistical Computing Environment, the company said, covering trial data from the start of a study to the regulatory filing. Data from labs, patients, trial sites and digital health sensors lands in a single governed system the moment it is produced, according to nPhase, instead of being reconciled after a study ends.
The company said AI agents handle high-volume chores such as flagging discrepancies in incoming data and drafting statistical programming code, while human experts keep final say on decisions.
nPhase also sells REDCap Cloud, an electronic data capture product it markets to smaller sponsors, academic and nonprofit researchers, medtech studies and programs that collect real-world data. Its customers are drug and device developers, but nPhase itself develops software, not therapies.
"We've built the unified, governed data foundation that makes AI possible across the clinical data lifecycle," Scott Climes, nPhase's chief executive, said in the announcement.
Levi Malik, a principal at Viking, described the opportunity in broader terms. "We see a significant opportunity to modernize how the life sciences industry manages and uses clinical data," Malik said.
What comes next
nPhase said the money will help it grow its clinical data business with large customers and expand the Statistical Computing Environment, the data management system and its agentic AI features. The announcement's headline framed the round around global expansion, though the release did not name target countries.
The company did not disclose revenue, customer names or how much it has raised in total since its founding. The release also gave no timeline for the next AI features it plans to ship.



